 |
|
|
| |
The Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (EVG/COBI/FTC/TDF; "QUAD") Maintains a High Rate of Virologic Suppression, and Cobicistat (COBI) is an Effective Pharmacoenhancer Through 48 Weeks
|
| |
| |
Reported by Jules Levin
ICAAC Sept 14 2010 Boston
R Elion,1 J Gathe,2 B Rashbaum,3 P Shalit,4 T Hawkins,5 HC Liu,6 L Zhong,6 DR Warren,6 BP Kearnery,6 and SL Chuck6
1Whitman Walker Clinic, Washington, D.C.; 2Houston, TX; 3Washington, D.C.; 4Seattle, WA; 5Santa Fe, NM; 6Gilead Sciences, Inc., Foster City, CA
|
| |
|
|
|
|
|
